局部晚期非小细胞肺癌的治疗  

Progress of therapy for locally advanced non-small cell lung cancer

作　　者：刘晓洪(综述)[1] 陈辉(综述)[1] 陈怀云(审校)[1] 

机构地区：[1]湖北省襄樊市中心医院(华中科技大学同济医学院附属襄樊医院)肿瘤科,441021

出　　处：《国际肿瘤学杂志》2008年第3期195-198,共4页Journal of International Oncology

摘　　要：同步放化疗使局部晚期非小细胞肺癌（NSCLC）的5年生存率由单纯放疗的5％提高到目前的15％左右，是目前标准治疗模式。应用三维适形放疗技术，采用常规分割方式和累及野照射，给予肿瘤较高的剂量，以及同步放化疗后进行巩固化疗显示出更好的疗效；诱导化疗的作用尚不确定；分子靶向药物有较好的应用前景。The 5-year survival rate of patients with locally advanced non-small cell lung cancer has been raised to 15% from 5% by concurrent ehemoradiotberapy（CRT） and CRT has been accepted as standard treatment for these patients. CRT using three-dimensional eonformal radiotherapy technique, conventional fraction, and involved field irradiation followed by consolidation chemotherapy yields better outcome. The role of induction chemotherapy remains obscure. Target therapy strategy is promising.

关 键 词：癌 非小细胞肺 放射疗法 药物疗法 

分 类 号：R734.2[医药卫生—肿瘤]